| |MAY 20268TOP STORIESCOULD BUNDIBUGYO VIRUS TRIGGER THE NEXT EBOLA SCARE?INDIA GETS BREAKTHROUGH ALZHEIMER'S DRUG LORMALZIINDOCO REMEDIES EYES EUROPEAN ENTRY AFTER EU GMP CERTIFICATIONHOW KARNATAKA IS SHUTTING DOWN SUBSTANDARD MEDICINESTELANGANA LIFE SCIENCES ECOSYSTEM HITS 145 BILLION USD VALUATIONThe Bundibugyo virus is once again becoming a global health concern as scientists and health agencies closely monitor the latest Ebola outbreak in Central Africa. The rare virus, which belongs to the Ebola family, has sparked fresh fears after the World Health Organization (WHO) declared the ongoing outbreak an international public health emergency. Health experts warn that the Bundibugyo virus remains one of the lesser-understood Ebola strains, with no approved vaccine or specific antiviral treatment currently available. First identified in Uganda's Bundibugyo district in 2007, the virus is known to cause severe hemorrhagic fever in humans. Symptoms usually begin with fever, fatigue, headaches, and muscle pain before progressing into vomiting, internal bleeding, and organ failure in severe cases. PO The breakthrough Alzheimer's drug Lormalzi launched in India by Eli Lilly and Company, is giving fresh hope to patients and doctors battling one of the world's fastest-growing neurological disorders. The launch of Lormalzi marks a major step forward in Alzheimer's treatment because the therapy is designed to slow the progression of the disease instead of only managing symptoms.Neurologists say the arrival of Lormalzi could transform dementia care in India, especially for patients diagnosed in the early stages of Alzheimer's disease. The introduction of Lormalzi comes at a crucial time as India witnesses a steady rise in dementia and age-related cognitive disorders. Experts believe Indoco Remedies Ltd. has announced that its manufacturing facility for solid oral dosage forms (Unit I) located at Baddi, Himachal Pradesh has received EU GMP (Good Karnataka has taken a giant leap in public health governance by launching its drug monitoring portal that automatically blocks the sale of substandard medicines. The portal was launched by Karnataka Health Minister Dinesh Gundu Rao on Thursday. Until now, the substandard medicines were dealt with in a highly reactive way. By the time a drug sample was collected, tested and declared Not of Standard Quality (NSQ), it had already spread deep into the supply chain. There was no structured mechanism to recall the batches, and hence it could be purchased and sold to patients. This initiative addresses that systematic gap. The officials shared that the Food Safety and Drug Administration Department had recalled medicines worth Rs 1.85 Cr in the year 2025-2026. POTelangana's life sciences ecosystem has reached a landmark $145 billion valuation, marking a major milestone in India's pharmaceutical industry and biotechnology sectors. The achievement comes amid rising investments, policy support, and Hyderabad's emergence as a global healthcare innovation hub.Backed by over Rs 84,000 crore investments in the last two years, Telangana has strengthened its position as a preferred destination for pharmaceutical manufacturing, biotechnology, medical devices, and healthcare research. Officials said the state's life sciences industry has nearly tripled in size since 2016, reflecting rapid expansion across multiple healthcare segments. POawareness around memory-related illnesses has improved in recent years, but early diagnosis remains one of the country's biggest healthcare challenges. PO Manufacturing Practice) certificate from the Malta Medicines Authority, marking the company's first step to European entry.Indoco gained the EU GMP certification after a successful inspection at its Baddi unit between January 29 and February 3, 2026. This certification confirms that the company solid oral dosage manufacturing meets the stringent quality and safety standards required under European Union regulations. PO
< Page 7 | Page 9 >